Company patents
GENFIT
GENFIT's patent strategy is heavily concentrated in core pharma_biotech areas, with 'Pharmaceutical Preparations' and 'Therapeutic Activity (Pharma)' accounting for 77.6% and 65.3% of its portfolio, respectively. While these categories saw significant growth in 2024 (YoY +128.6% and +116.7%), there's a surprising decline in patenting activity across most categories in 2025 and so far in 2026, including a complete cessation of new patents in 'Healthcare Informatics' and 'Genetic & Microbiological Assays' in 2026, suggesting a potential shift in R&D focus or a more selective patenting approach.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
49 US filings (since 2023) · 12 categories · 3 themes
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Patents
Showing 41-50 of 82